Evidence map›Paper›PMID 26097600›Full record

ArticleInternational journal of clinical and experimental pathology2015

Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.

Bateer Han, Zhanlin Guo, Ying Ma, Shirong Kang, Yufei Wang, Qiyou Wei, Xu Wu

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pharmacogenetic Association betweenBioMed research international · 2020
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bateer HanDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University Guangzhou 510515, China ; Department of Thoracic Surgery, Affiliated People's Hospital of Inner Mongolia Medical University Hohhot 010020, China.
Zhanlin GuoDepartment of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050, China.
Ying MaDepartment of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050, China.
Shirong KangDepartment of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050, China.
Yufei WangDepartment of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University Hohhot 010050, China.
Qiyou WeiDepartment of Thoracic Surgery, Affiliated People's Hospital of Inner Mongolia Medical University Hohhot 010020, China.
Xu WuDepartment of Thoracic Surgery, Nanfang Hospital, Southern Medical University Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the association between the clinical outcome and GSTP1 and XRCC1 gene polymorphisms in advanced NSCLC patients with cisplatin-based chemotherapy. We prospectively recruited 325 NSCLC patients between January 2010 and January 2014. Genotypes of GSTP1 A313G, XRCC1 Arg194Trp, Arg280His and Arg399Gln were conducted using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay. AG and GG genotypes of GSTP1 A313G were correlated with a higher CR + PR when compared with AA genotype. Furthermore, GA and AA genotypes of XRCC1 Arg399Gln were associated with more CR + PR when compared with GG genotype. In the Cox proportional hazards model, GG genotype of GSTP1 A313G was significantly correlated with a longer median survival time when compared with AA genotype, and it is associated with a heavy decreased risk of death from NSCLC. Moreover, GA and AA genotypes of XRCC1 Arg399Gln had a significantly longer median survival time, and GA and AA genotypes were significantly associated with a moderate reduced risk of death from NSCLC. GSTP1 A313G and XRCC1 Arg399Gln gene polymorphisms might influence the response to cisplatin-based chemotherapy and affect the clinical outcome of advanced NSCLC.

Indexed as

Polymorphism, GeneticAdenocarcinomaAdenocarcinoma of LungAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChi-Square DistributionCisplatinDNA-Binding ProteinsFemaleGene FrequencyGenetic Predisposition to DiseaseGlutathione S-Transferase piHumansBiomarkers, TumorCisplatinDNA-Binding ProteinsGlutathione S-Transferase piGSTP1 protein, humanX-ray Repair Cross Complementing Protein 1XRCC1 protein, humancisplatin-based chemotherapyGSTP1non-small cell lung cancerpolymorphismXRCC1

Identifiers

PMID26097600
PMCPMC4466987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.